Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease

Biomaterials

Volumn 31, Issue 23, 2010, Pages 6031-6038

  Bastiat, Guillaume ^a   Plourde, François ^a   Motulsky, Aude ^a   Furtos, Alexandra ^a   Dumont, Yvan ^b   Quirion, Rémi ^b   Fuhrmann, Gregor ^a,c   Leroux, Jean Christophe ^a,c  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^c ETH ZURICH   (Switzerland)

Author keywords

AChE inhibition; Alzheimer's disease; Biocompatibility; Organogel; Pharmacokinetic; Rivastigmine

Indexed keywords

ACETYLCHOLINESTERASE; ACHE INHIBITION; ALTERNATIVE APPROACH; ALZHEIMER'S DISEASE; BRAIN STRUCTURE; CHRONIC INFLAMMATION; DRUG CONCENTRATION; GEL COMPOSITIONS; GELATOR MOLECULES; GLYCOLIDE; IN-SITU; IN-VIVO; L-LACTIDE; LOW MOLECULAR WEIGHT; ORGANIC PHASE; ORGANO-GELATOR; ORGANOGEL SYSTEMS; ORGANOGELS; PHARMACOKINETIC PROFILES; RIVASTIGMINE; THREE-DIMENSIONAL NETWORKS;

AMINO ACIDS; BIOCOMPATIBILITY; CONTROLLED DRUG DELIVERY; GELS; ORGANIC POLYMERS; PHARMACOKINETICS; PHOSPHATASES; VEGETABLE OILS;

DISEASES;

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; POLYGLACTIN; RIVASTIGMINE; TYROSINE; CARBAMIC ACID DERIVATIVE; GEL; NEUROPROTECTIVE AGENT;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOCOMPATIBILITY; BRAIN TISSUE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROSIS; GEL; HIPPOCAMPUS; IMPLANT; IN VIVO STUDY; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RAT; SUSTAINED RELEASE FORMULATION; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; CHEMISTRY; HUMAN;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; CHROMATOGRAPHY, LIQUID; GELS; HUMANS; NEUROPROTECTIVE AGENTS; PHENYLCARBAMATES; TANDEM MASS SPECTROMETRY; TYROSINE;

CARTHAMUS TINCTORIUS;

EID: 77953807285     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.04.009     Document Type: Article

References (51)

1. Ajayaghosh A., Praveen V.K., Vijayakumar C. Organogels as scaffolds for excitation energy transfer and light harvesting. Chem Soc Rev 2008, 37:109-122.
2. Carretti E., Dei L., Weiss R.G. Soft matter and art conservation. Rheoreversible gels and beyond. Soft Matter 2005, 1:17-22.
3. Pernetti M., van Malssen K.F., Flöter E., Bot A. Structuring of edible oil by alternatives to crystalline fat. Curr Opin Colloid Interf Sci 2007, 12:221-231.
4. Pisal S., Shelke V., Mahadik K., Kadam S. Effect of organogel components on in vitro nasal delivery of propranolol hydrochloride. AAPS PharmSciTech 2004, 5:e63.
5. Upadhyay K.K., Tiwari C., Khopade A.J., Bohidar H.B., Jain S.K. Sorbitan ester organogels for transdermal delivery of sumatriptan. Drug Dev Ind Pharm 2007, 33:617-625.
6. Jones D.S., Muldoon B.C., Woolfson A.D., Andrews G.P., Sanderson F.D. Physicochemical characterization of bioactive polyacrylic acid organogels as potential antimicrobial implants for the buccal cavity. Biomacromolecules 2008, 9:624-633.
7. Agrawal G.P., Juneja M., Agrawal S., Jain S.K., Pancholi S.S. Preparation and characterization of reverse micelle based organogels of piroxicam. Pharmazie 2004, 59:191-193.
8. Paice J.A., Von Roenn J.H., Hudgins J.C., Luong L., Krejcie T.C., Avram M.J. Morphine bioavailability from a topical gel formulation in volunteers. J Pain Symptom Manag 2008, 35:314-320.
9. Shaikh I.M., Jadhav K.R., Gide P.S., Kadam V.J., Pisal S.S. Topical delivery of aceclofenac from lecithin organogels: preformulation study. Curr Drug Deliv 2006, 3:417-427.
10. Lim P.F.C., Liu X.Y., Kang L., Ho P.C.L., Chan Y.W., Chan S.Y. Limonene GP1/PG organogel as a vehicle in transdermal delivery of haloperidol. Int J Pharm 2006, 311:157-164.
11. Cui Z., Mumper R.J. Bilayer films for mucosal (genetic) immunization via the buccal route in rabbits. Pharm Res 2002, 19:947-953.
12. Murdan S., Andrysek T., Son D. Novel gels and their dispersions-oral drug delivery systems for ciclosporin. Int J Pharm 2005, 300:113-124.
13. Mahler P., Mahler F., Duruz H., Ramazzina M., Liguori V., Mautone G. Double-blind, randomized, controlled study on the efficacy and safety of a novel diclofenac epolamine gel formulated with lecithin for the treatment of sprains, strains and contusions. Drugs Exp Clin Res 2003, 29:45-52.
14. Spacca G., Cacchio A., Forgács A., Monteforte P., Rovetta G. Analgesic efficacy of a lecithin-vehiculated diclofenac epolamine gel in shoulder periarthritis and lateral epicondylitis: a placebo-controlled, multicenter, randomized, double-blind clinical trial. Drugs Exp Clin Res 2005, 31:147-154.
15. Aboofazeli R., Zia H., Needham T.E. Transdermal delivery of nicardipine: an approach to in vitro permeation enhancement. Drug Deliv 2002, 9:239-247.
16. Murdan S., Gregoriadis G., Florence A.T. Sorbitan monostearate/polysorbate 20 organogels containing niosomes: a delivery vehicle for antigens?. Eur J Pharm Sci 1999, 8:177-185.
17. Vintiloiu A., Leroux J.C. Organogels and their use in drug delivery - a review. J Control Release 2008, 125:179-192.
18. Ruel-Gariépy E., Shive M., Bichara A., Berrada M., Le Garrec D., Chenite A., et al. A thermosensitive chitosan-based hydrogel for the local delivery of paclitaxel. Eur J Pharm Biopharm 2004, 57:53-63.
19. Mäder K., Bittner B., Li Y., Wohlauf W., Kissel T. Monitoring microviscosity and microacidity of the albumin microenvironment inside degrading microparticles from poly(lactide-co-glycolide) (PLG) or ABA-triblock polymers containing hydrophobic poly(lactide-co-glycolide) A blocks and hydrophilic poly(ethyleneoxide) B blocks. Pharm Res 1998, 15:787-793.
20. Gao Z.H., Crowley W.R., Shukla A.J., Johnson J.R., Reger J.F. Controlled release of contraceptive steroids from biodegradable and injectable gel formulations: in vivo evaluation. Pharm Res 1995, 12:864-868.
21. Couffin-Hoarau A.C., Motulsky A., Delmas P., Leroux J.C. In situ-forming pharmaceutical organogels based on the self-assembly of L-alanine derivatives. Pharm Res 2004, 21:454-457.
22. Bastiat G., Leroux J.C. Pharmaceutical organogels prepared from aromatic amino acid derivatives. J Mater Chem 2009, 19:3867-3877.
23. Becci P.J., Gephart L.A., Koschier F.J., Johnson W.D., Burnette L.W. Subchronic feeding study in beagle dogs of N-methylpyrrolidone. J Appl Toxicol 1983, 3:83-86.
24. Motulsky A., Lafleur M., Couffin-Hoarau A.C., Hoarau D., Boury F., Benoit J.P., et al. Characterization and biocompatibility of organogels based on L-alanine for parenteral drug delivery implants. Biomaterials 2005, 26:6242-6253.
25. Plourde F., Motulsky A., Couffin-Hoarau A.C., Hoarau D., Ong H., Leroux J.C. First report on the efficacy of L-alanine-based in situ-forming implants for the long-term parenteral delivery of drugs. J Control Release 2005, 108:433-441.
26. Vintiloiu A., Lafleur M., Bastiat G., Leroux J.C. In situ-forming oleogel implant for rivastigmine delivery. Pharm Res 2008, 25:845-852.
27. Kurz A., Farlow M., Lefevre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. Int J Clin Pract 2009, 63:799-805.
28. Ellman G.L., Courtney K.D., Andres V., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961, 7:88-95.
29. Luna L.G. Manual of histologic staining methods of the armed forces institute of pathology 1960, McGraw-Hill, New York. L.G. Luna (Ed.).
30. Anderson J.M. Biological responses to materials. Ann Rev Mater Res 2001, 31:81-110.
31. Shapira M., Grant A., Korner M., Soreq H. Genomic and transcriptional characterization of the human AChE locus: complex involvement with acquired and inherited diseases. Isr Med Assoc J 2000, 2:470-473.
32. Kaufer D., Friedman A., Seidman S., Soreq H. Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998, 393:373-377.
33. Onor M.L., Trevisiol M., Aguglia E. Rivastigmine in the treatment of Alzheimer's disease: an update. Clin Interv Aging 2007, 2:17-32.
34. Barnes J., Barlett J.W., van de Pol L.A., Loy C.T., Scahill R.I., Frost C., et al. A meta-analysis of hippocampal atrophy rates in Alzheimer's disease. Neurobiol Aging 2009, 30:1711-1723.
35. Williams B.R., Nazarians A., Gill M.A. A review of rivastigmine: a reversible cholinesterase inhibitor. Clin Ther 2003, 25:1634-1653.
36. Cohen N.J., Ryan J., Hunt C., Romine L., Wszalek T., Nash C. Hippocampal system and declarative (relational) memory: summarizing the data from functional neuroimaging studies. Hippocampus 1999, 9:83-98.
37. Moses S.N., Ryan J. A comparison and evaluation of the predictions of relational and conjunctive accounts of hippocampal function. Hippocampus 2006, 16:43-65.
38. Winblad B., Cummings J., Andreasen N., Grossberg G., Onofrj M., Sadowsky C., et al. A six-month double-bind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriat Psychiatry 2007, 22:456-467.
39. Winblad B., Kawata A.K., Beusterien K.M., Thomas S.K., Wimo A., Lane R., et al. Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease. Int J Geriat Psychiatry 2007, 22:485-491.
40. Mauskopf J.A., Paramore C., Lee W.C., Snyder E.H. Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings. J Managed Care Pharm 2005, 11:231-239.
41. Blais L., Kettani F.Z., Perreault S., Leroux J.C., Forget A., Kergoat M.J. Adherence to cholinesterase inhibitors in patients with Alzheimer's disease. J Am Geriat Soc 2009, 57:366-367.
42. Cummings J., Lefèvre G., Small G., Appel-Dingemanse S. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007, 69:S10-S13.
43. Yang Q., Williams D., Owusu-Ababio G., Ebube N.K., Habib M.J. Controlled release tacrine delivery system for the treatment of Alzheimer's disease. Drug Deliv 2001, 8:93-98.
44. Gao P., Ding P., Xu H., Yuan Z., Chen D., Wei J., et al. In vitro and in vivo characterization of huperzine A loaded microspheres made from end-group uncapped poly(d, l-lactide acid) and poly(d, l-lactide-co-glycolide acid). Chem Pharm Bull 2006, 54:89-93.
45. Fu X., Ping Q., Gao Y. Effects of formulation factors on encapsulation efficiency and release behaviour in vitro of huperzine A-PLGA microspheres. J Microencapsulation 2005, 22:705-714.
46. Gao P., Xu H., Ding P., Gao Q., Sun J., Chen D. Controlled release of huperzine A from biodegradable microspheres: in vivo and in vitro studies. Int J Pharm 2007, 330:1-5.
47. Chu D.F., Fu X.Q., Liu W.H., Liu K., Li Y.X. Pharmacokinetics and in vitro and in vivo correlation of huperzine A loaded poly(lactic-co-glycolic acid) microspheres in dogs. Int J Pharm 2006, 325:116-123.
48. Zhang P., Chen L., Gu W., Xu Z., Gao Y., Li Y. In vitro and in vivo evaluation of donepezil-sustained release microparticles for the treatment of Alzheimer's disease. Biomaterials 2007, 28:1882-1888.
49. Coppack S.W., Yost T.J., Fisher R.M., Eckel R.H., Miles J.M. Periprandial systemic and regional lipase activity in normal humans. Am J Physiol Endocrinol Metab 1996, 270:E718-E722.
50. Jeong B., Choi Y.K., Bae Y.H., Zentner G., Kim S.W. New biodegradable polymers for injectable drug delivery systems. J Control Release 1999, 62:109-114.
51. Yamaguchi K., Anderson J.M. In vivo biocompatibility studies of medisorb 65/35 D, L-lactide/glycolide copolymer microspheres. J Control Release 1993, 24:81-93.